Top

Published in:

01-08-2014 | Review Article

Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

Authors: Heather L. McGinty, Kristin M. Phillips, Heather S. L. Jim, Julie M. Cessna, Yasmin Asvat, Mallory G. Cases, Brent J. Small, Paul B. Jacobsen

Published in: Supportive Care in Cancer | Issue 8/2014

Abstract

Purpose

Prior research examining the impact of androgen deprivation therapy (ADT) for prostate cancer on cognitive performance has found inconsistent relationships. The purpose of this study was to systematically review the existing literature and determine the effect of ADT on performance across seven cognitive domains using meta-analysis.

Methods

A search of PubMed Medline, PsycINFO, Cochrane Library, and Web of Knowledge/Science databases yielded 157 unique abstracts reviewed by independent pairs of raters. Fourteen studies with a total of 417 patients treated with ADT were included in the meta-analysis. Objective neuropsychological tests were categorized into seven cognitive domains: attention/working memory, executive functioning, language, verbal memory, visual memory, visuomotor ability, and visuospatial ability.

Results

Separate effect sizes were calculated for each cognitive domain using pairwise comparisons of patients who received ADT with (1) prostate cancer patient controls, (2) noncancer controls, or (3) ADT patients’ own pre-ADT baselines. Patients treated with ADT performed worse than controls or their own baseline on visuomotor tasks (g = −0.67, p = .008; n = 193). The magnitude of the deficits was larger in studies with a shorter time to follow-up (p = .04). No significant effect sizes were observed for the other six cognitive domains (p = .08–.98).

Conclusions

Prostate cancer patients who received ADT performed significantly worse on visuomotor tasks compared to noncancer control groups. These findings are consistent with the known effects of testosterone on cognitive functioning in healthy men. Knowledge of the cognitive effects of ADT may help patients and providers better understand the impact of ADT on quality of life.

Available only for authorised users

National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology version 2: 2013 Prostate cancer information. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 01 June 2013

Alibhai SMH, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60:201–215. doi:10.1016/j.critrevonc.2006.06.006 PubMedCrossRef

Akaza H (2011) Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci 102:51–56. doi:10.1111/j.1349-7006.2010.01774.x PubMedCrossRef

Kumar R, Barqawi A, Crawford ED (2005) Preventing and treating the complications of hormone therapy. Curr Urol Rep 6:217–223. doi:10.1007/s11934-005-0010-9 PubMedCrossRef

Holland J, Bandelow S, Hogervorst E (2011) Testosterone levels and cognition in elderly men: a review. Maturitas 69:322–337. doi:10.1016/j.maturitas.2011.05.012 PubMedCrossRef

Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM (2002) Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 87:5001–5007. doi:10.1210/jc.2002-020419 PubMedCrossRef

Thilers PP, MacDonald SWS, Herlitz A (2006) The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 31:565–576. doi:10.1016/j.psyneuen.2005.12.005 PubMedCrossRef

Linn MC, Petersen AC (1985) Emergence and characterization of sex differences in spatial ability: a meta-analysis. Child Dev 56:1479–1498. doi:10.2307/1130467 PubMedCrossRef

Voyer D, Voyer S, Bryden MP (1995) Magnitude of sex differences in spatial abilities: a meta-analysis and consideration of critical variables. Psychol Bull 117:250–270. doi:10.1037/0033-2909.117.2.250 PubMedCrossRef

10.

Nelson CJ, Lee JS, Gamboa MC, Roth AJ (2008) Cognitive effects of hormone therapy in men with prostate cancer. Cancer 113:1097–1106. doi:10.1002/cncr.23658 PubMedCrossRef

11.

Jamadar RJ, Winters MJ, Maki PM (2012) Cognitive changes associated with ADT: a review of the literature. Asian J Androl 14:232–238. doi:10.1038/aja.2011.107 PubMedCentralPubMedCrossRef

12.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269. doi:10.1371/journal.pmed.1000097 PubMedCrossRef

13.

Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment, 4th edn. Oxford University Press, New York

14.

Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, San Diego

15.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. doi:10.1016/0197-2456(86)90046-2 PubMedCrossRef

16.

Orwin RG (1983) A fail-safe N for effect size in meta-analysis. J Educ Stat 8:157–159CrossRef

17.

Salminen E, Portin R, Korpela J, Backman H, Parvinen L-M, Helenius H, Nurmi M (2003) Androgen deprivation and cognition in prostate cancer. Br J Cancer 89:971–976. doi:10.1038/sj.bjc.6601235 PubMedCentralPubMedCrossRef

18.

Alibhai SMH, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, Naglie G et al (2010) Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol 28:5030–5037. doi:10.1200/JCO.2010.30.8742 PubMedCrossRef

19.

Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, MacTaggart PN, Swanson CE et al (2002) Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90:427–432. doi:10.1046/j.1464-4096.2002.02917.x PubMedCrossRef

20.

Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, MacTaggart PN, Swanson CE et al (2004) Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93:975–979. doi:10.1111/j.1464-410X.2004.04763.x PubMedCrossRef

21.

Matousek RH, Sherwin BB (2010) A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology 35:215–225. doi:10.1016/j.psyneuen.2009.06.012 PubMedCrossRef

22.

Cherrier MM, Borghesani PR, Shelton AL, Higano CS (2010) Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study. BMC Cancer 10:1–8. doi:10.1186/1471-2407-10-1 PubMedCentralPubMedCrossRef

23.

Bussiere JR, Beer TM, Neiss MB, Janowsky JS (2005) Androgen deprivation impairs memory in older men. Behav Neurosci 119:1429–1437. doi:10.1037/0735-7044.119.6.1429 PubMedCrossRef

24.

Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL (2007) Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther 87:1325–1333. doi:10.2522/ptj.20060302 PubMedCrossRef

25.

Jim HSL, Small BJ, Patterson S, Salup R, Jacobsen PB (2010) Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer 18:21–27. doi:10.1007/s00520-009-0625-3 PubMedCrossRef

26.

Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN (2004) One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29:1071–1081. doi:10.1016/j.psyneuen.2003.11.002 PubMedCrossRef

27.

Cherrier MM, Rose AL, Higano C (2003) The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170:1808–1811. doi:10.1097/01.ju.0000091640.59812.83 PubMedCrossRef

28.

Cherrier MM, Aubin S, Higano CS (2009) Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 18:237–247. doi:10.1002/pon.1401 PubMedCrossRef

29.

Jenkins VA, Bloomfield DJ, Shilling VM, Edington TL (2005) Does neoadjuvant hormone therapy for early prostate cancer affect cognition? results from a pilot study. BJU Int 96:48–53. doi:10.1111/j.1464-410X.2005.05565.x PubMedCrossRef

30.

Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Stradler WM (2010) Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. J Geriatr Oncol 1:13–19. doi:10.1016/j.critrevonc.2010.06.009 CrossRef

31.

Galvao DA, Joseph D, Spry N, Joseph D, Turner D, Newton RU (2008) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12:198–203. doi:10.1038/pcan.2008.51 PubMedCrossRef

32.

Smith MR, Finkelstein JS, McGovern FJ, Zeitman AL, Fallon MA, Schoenfeld DA, Kantoff PW (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599–603PubMedCrossRef

33.

Smith MR (2004) Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 63:742–745. doi:10.1016/j.urology.2003.10.063 PubMedCrossRef

34.

Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M et al (2008) Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 72:422–427. doi:10.1016/j.urology.2008.03.032 PubMedCentralPubMedCrossRef

35.

Anderson-Hanley CAY, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9:967–982. doi:10.1017/S1355617703970019 PubMedCrossRef

36.

Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222–2233. doi:10.1002/cncr.21469 PubMedCrossRef

37.

Jim HSL, Phillips KM, Chait S, Faul LA, Popa MA, Lee Y-M, Hussin MG et al (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578–3587. doi:10.1200/JCO.2011.39.5640 PubMedCentralPubMedCrossRef

38.

Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ et al (2008) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110:143–152. doi:10.1007/s10549-007-9686-5 PubMedCentralPubMedCrossRef

39.

Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG et al (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32:324–331. doi:10.1080/13803390903032537 PubMedCrossRef

40.

Meyers CA, Byrne KS, Komaki R (1995) Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12:231–235PubMedCrossRef

41.

Schagen SB, van Dam FSAM (2006) Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? J Clin Oncol 24:5170–5171. doi:10.1200/JCO.2006.07.8303 PubMedCrossRef

Title: Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis
Authors: Heather L. McGinty
Kristin M. Phillips
Heather S. L. Jim
Julie M. Cessna
Yasmin Asvat
Mallory G. Cases
Brent J. Small
Paul B. Jacobsen
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 8/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2285-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2014

Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study

Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients

Monitoring changes in quality of life in patients with lung cancer by using specialised questionnaires: implications for clinical practice

Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma

Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction

Perceptions of risk among childhood and young adult cancer survivors who smoke

Keynote webinar | Spotlight on antibody–drug conjugates in cancer